Sanofi Re-Launches Rolaids in U.S. - Analyst Blog

By
A A A
Share |

Sanofi 's ( SNY ) U.S. consumer healthcare division, Chattem, Inc., recently re-launched an over-the-counter antacid Rolaids in the U.S. Rolaids is now available in both tablets and liquid formulation.

We note that in Jan 2013, Sanofi acquired worldwide rights to Rolaids from McNeil Consumer Healthcare, a subsidiary of Johnson and Johnson ( JNJ ).

Sanofi is one of the major players in the consumer health care market in the US. The company provides a strong platform for the potential conversion of prescription medicines to OTC status in the U.S. We are positive on the addition of Rolaids to Sanofi's consumer healthcare portfolio, which includes products such as Allegra over-the-counter, Icy Hot, Gold Bond, Cortizone-10, Selsun Blue, ACT and Unisom.

Sanofi, a large-cap pharma company, carries a Zacks Rank #5 (Strong Sell). We are concerned about the generic threat confronting most of Sanofi's key drugs. Additionally, recent pipeline failures (oncology candidate - iniparib and anticoagulant - otamixaban) have put immense pressure on Sanofi's pipeline.

Additionally, Sanofi recently announced its decision to withdraw the new drug application (NDA) for lixisenatide in the U.S. Sanofi is looking to get the drug approved for the treatment of adults with type II diabetes.

The NDA included early interim data from the ongoing ELIXA cardiovascular (CV) outcomes study. The company believes that potential public disclosure will hamper the integrity of the ELIXA CV study, which is expected to be complete in the next 15 months. Sanofi intends to resubmit the NDA for lixisenatide in 2015, post completion of the ELIXA CV study.

Not all large-cap pharma companies are performing as badly as Sanofi. Novo Nordisk ( NVO ) and Bayer ( BAYRY ) are well placed with a Zacks Rank #2 (Buy).



BAYER A G -ADR (BAYRY): Free Stock Analysis Report

JOHNSON & JOHNS (JNJ): Free Stock Analysis Report

NOVO-NORDISK AS (NVO): Free Stock Analysis Report

SANOFI-AVENTIS (SNY): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research



The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.



This article appears in: Investing , Business , Stocks

Referenced Stocks: BAYRY , JNJ , NVO , SNY

Zacks.com

Zacks.com

More from Zacks.com:

Related Videos

Stocks

Referenced

Most Active by Volume

89,970,926
  • $16.15 ▲ 0.12%
77,131,582
  • $58.94 ▼ 1.31%
67,336,935
  • $26.56 ▲ 1.68%
48,814,124
  • $86.20 ▲ 0.02%
47,526,126
  • $23.21 ▲ 0.78%
44,660,424
  • $23.91 ▲ 6.36%
38,799,699
  • $4.289 ▲ 4.36%
36,199,890
  • $40.01 ▼ 0.97%
As of 4/17/2014, 04:07 PM